The authors have tried a new drug isodibut, aldoreductase inhibitor, of Russian produce in 53 patients with diabetes mellitus. A course of isodibut++ has improved blood coagulation and fibrinolysis, microcirculatory blood flow, normalized muscular blood flow as indicated by electrocoagulation, conjunctival biomicroscopy, radionuclide tracing. The drug is recommended for treatment and prevention of diabetic angiopathy.

01 Jan 1990·Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952)

[Autonomic polyneuropathies in diabetes mellitus (the problems of the clinical picture and treatment)].

Article

Author: Danilov, A B

Patients with diabetic somatic and vegetative polyneuropathies were subjected to clinical and laboratory studies before and after treatment with the new Soviet drug isodibut. The drug has turned out to be highly efficacious in the treatment of vegetative peripheral insufficiency.

Problemy endokrinologii

[Submicroscopic restructurings in the glomerular portion of the rat nephron in streptozotocin diabetes and their possible drug correction].

Article

Author: Efimov, A S ; Mel'nik, I M ; Zurnadzhi, Iu N ; Bragarnik, M N ; Bogdanova, T I

Experiments on Wistar male rats have shown that in 2 weeks the administration of streptozotocin results in an increase in relative kidney mass by 23%, the development of submicroscopic rearrangements indicating the hypertrophy of the main glomerular components and the acceleration of ultrafiltration. In one month a sharp widening of the lumens of capillaries and intersubosseous spaces, inflammatory symptoms, and signs of primary urine congestion are noted in parallel with hypertrophic changes. The relative kidney mass increases by 73.5% (p less than 0.01). The use of the aldose reductase blocker isodibut prevents, to a great extent, the development of ultrastructural changes in a glomerulus detected one month after administration of streptozotocin, improves ultrafiltration and inhibits a sharp increase in kidney mass, i. e. it prevents disorder of renal excretory function at the initial stages of experimental diabetes.

100 Deals associated with Isodibut

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Isodibut

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation